| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 70 | 2024 | 195 | 22.940 |
Why?
|
| Tuberculosis | 46 | 2024 | 121 | 17.300 |
Why?
|
| Tuberculosis, Pulmonary | 25 | 2024 | 58 | 7.240 |
Why?
|
| Interleukin-17 | 26 | 2020 | 105 | 5.410 |
Why?
|
| Tuberculosis Vaccines | 11 | 2024 | 17 | 4.760 |
Why?
|
| Lung | 38 | 2024 | 1243 | 4.430 |
Why?
|
| Latent Tuberculosis | 13 | 2022 | 16 | 3.460 |
Why?
|
| Immunity, Innate | 18 | 2024 | 427 | 3.460 |
Why?
|
| Th17 Cells | 13 | 2020 | 84 | 3.330 |
Why?
|
| BCG Vaccine | 8 | 2024 | 35 | 2.640 |
Why?
|
| Rifampin | 6 | 2024 | 23 | 2.550 |
Why?
|
| Cytokines | 15 | 2024 | 801 | 2.540 |
Why?
|
| Interleukin-23 | 12 | 2019 | 57 | 2.520 |
Why?
|
| Dendritic Cells | 13 | 2020 | 436 | 2.350 |
Why?
|
| Animals | 100 | 2024 | 27203 | 2.260 |
Why?
|
| Mice | 59 | 2024 | 11700 | 2.250 |
Why?
|
| Mice, Knockout | 31 | 2024 | 1987 | 2.220 |
Why?
|
| CD4-Positive T-Lymphocytes | 15 | 2021 | 439 | 2.180 |
Why?
|
| Mice, Inbred C57BL | 40 | 2024 | 3198 | 2.100 |
Why?
|
| Interleukins | 12 | 2022 | 136 | 2.040 |
Why?
|
| Macrophages | 12 | 2022 | 572 | 2.020 |
Why?
|
| Calgranulin B | 4 | 2023 | 16 | 2.010 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 8 | 2023 | 135 | 2.000 |
Why?
|
| Granuloma | 12 | 2022 | 65 | 1.920 |
Why?
|
| DNA-Directed RNA Polymerases | 4 | 2024 | 103 | 1.900 |
Why?
|
| Lymphoid Tissue | 8 | 2023 | 57 | 1.890 |
Why?
|
| Vaccines | 4 | 2024 | 82 | 1.890 |
Why?
|
| Interferon Type I | 4 | 2024 | 177 | 1.810 |
Why?
|
| Signal Transduction | 17 | 2024 | 3366 | 1.770 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 4 | 2021 | 102 | 1.720 |
Why?
|
| Mycobacterium bovis | 5 | 2024 | 16 | 1.630 |
Why?
|
| Bacterial Proteins | 8 | 2024 | 885 | 1.630 |
Why?
|
| Interleukin-12 | 7 | 2019 | 109 | 1.590 |
Why?
|
| Influenza, Human | 4 | 2022 | 333 | 1.550 |
Why?
|
| Chemokines | 5 | 2020 | 74 | 1.530 |
Why?
|
| Immunity, Mucosal | 7 | 2020 | 69 | 1.500 |
Why?
|
| Chemokine CXCL13 | 7 | 2019 | 15 | 1.450 |
Why?
|
| Lymphocyte Activation | 9 | 2021 | 745 | 1.340 |
Why?
|
| Calgranulin A | 4 | 2023 | 11 | 1.340 |
Why?
|
| Th1 Cells | 8 | 2021 | 165 | 1.310 |
Why?
|
| Host-Pathogen Interactions | 5 | 2021 | 235 | 1.310 |
Why?
|
| Francisella tularensis | 4 | 2013 | 9 | 1.300 |
Why?
|
| Neutrophil Infiltration | 5 | 2020 | 28 | 1.300 |
Why?
|
| Inflammation | 10 | 2024 | 961 | 1.290 |
Why?
|
| Mycobacterium Infections | 3 | 2019 | 15 | 1.230 |
Why?
|
| Vaccination | 8 | 2024 | 269 | 1.200 |
Why?
|
| Chemokines, CXC | 3 | 2021 | 22 | 1.150 |
Why?
|
| Simian Acquired Immunodeficiency Syndrome | 8 | 2022 | 18 | 1.150 |
Why?
|
| Bacterial Infections | 2 | 2023 | 184 | 1.130 |
Why?
|
| Mucous Membrane | 4 | 2017 | 83 | 1.110 |
Why?
|
| Coinfection | 11 | 2022 | 59 | 1.110 |
Why?
|
| Killer Cells, Natural | 5 | 2022 | 274 | 1.100 |
Why?
|
| Humans | 85 | 2024 | 88482 | 1.090 |
Why?
|
| Phagocytes | 1 | 2024 | 11 | 0.980 |
Why?
|
| CD11c Antigen | 1 | 2024 | 13 | 0.980 |
Why?
|
| Interleukin-12 Subunit p40 | 6 | 2020 | 12 | 0.970 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2024 | 299 | 0.960 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 2024 | 6 | 0.960 |
Why?
|
| Cell Movement | 8 | 2019 | 783 | 0.930 |
Why?
|
| Saponins | 1 | 2024 | 42 | 0.920 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 1 | 2023 | 12 | 0.910 |
Why?
|
| Macaca mulatta | 22 | 2022 | 465 | 0.890 |
Why?
|
| T-Lymphocyte Subsets | 5 | 2013 | 275 | 0.850 |
Why?
|
| Adjuvants, Immunologic | 4 | 2024 | 168 | 0.850 |
Why?
|
| Biomarkers | 6 | 2024 | 1757 | 0.840 |
Why?
|
| Bronchi | 3 | 2019 | 229 | 0.840 |
Why?
|
| Antitubercular Agents | 5 | 2023 | 54 | 0.830 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2021 | 2 | 0.790 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2021 | 10 | 0.780 |
Why?
|
| Matrix Metalloproteinase 1 | 1 | 2021 | 17 | 0.780 |
Why?
|
| Disease Models, Animal | 18 | 2022 | 2343 | 0.760 |
Why?
|
| NF-kappa B | 1 | 2024 | 464 | 0.760 |
Why?
|
| Epithelial Cells | 4 | 2021 | 686 | 0.760 |
Why?
|
| Orthomyxoviridae Infections | 3 | 2022 | 46 | 0.760 |
Why?
|
| Neutrophils | 5 | 2024 | 308 | 0.750 |
Why?
|
| Lung Diseases | 2 | 2022 | 269 | 0.750 |
Why?
|
| Receptors, Immunologic | 1 | 2021 | 135 | 0.730 |
Why?
|
| B-Lymphocytes | 4 | 2023 | 736 | 0.730 |
Why?
|
| Macrophage Activation | 6 | 2024 | 49 | 0.730 |
Why?
|
| Simian Immunodeficiency Virus | 7 | 2022 | 17 | 0.700 |
Why?
|
| Immunologic Memory | 5 | 2021 | 161 | 0.690 |
Why?
|
| Dendritic Cells, Follicular | 1 | 2019 | 20 | 0.680 |
Why?
|
| Respiratory Tract Infections | 3 | 2022 | 107 | 0.670 |
Why?
|
| Granuloma, Respiratory Tract | 3 | 2013 | 4 | 0.670 |
Why?
|
| Receptors, CCR2 | 1 | 2018 | 35 | 0.640 |
Why?
|
| Cell Wall | 2 | 2018 | 66 | 0.640 |
Why?
|
| Receptors, CXCR5 | 4 | 2019 | 6 | 0.630 |
Why?
|
| Mycobacterium abscessus | 1 | 2018 | 2 | 0.630 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2018 | 48 | 0.630 |
Why?
|
| Aspergillus fumigatus | 1 | 2018 | 18 | 0.620 |
Why?
|
| Mycobacterium Infections, Nontuberculous | 1 | 2018 | 26 | 0.620 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 199 | 0.610 |
Why?
|
| Aspergillosis | 1 | 2018 | 41 | 0.610 |
Why?
|
| Glycolipids | 1 | 2017 | 29 | 0.600 |
Why?
|
| Germinal Center | 2 | 2023 | 55 | 0.600 |
Why?
|
| Lymphocytes | 5 | 2024 | 470 | 0.570 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 248 | 0.560 |
Why?
|
| Protein Subunits | 3 | 2006 | 123 | 0.540 |
Why?
|
| Interferon-gamma | 6 | 2011 | 451 | 0.530 |
Why?
|
| Adaptive Immunity | 7 | 2021 | 167 | 0.510 |
Why?
|
| Immunity, Cellular | 4 | 2020 | 178 | 0.510 |
Why?
|
| Lymphotoxin-alpha | 3 | 2017 | 44 | 0.510 |
Why?
|
| Female | 33 | 2024 | 45687 | 0.500 |
Why?
|
| Myeloid Cells | 6 | 2022 | 100 | 0.500 |
Why?
|
| Interleukin-10 | 3 | 2021 | 151 | 0.500 |
Why?
|
| Chemokine CCL19 | 4 | 2011 | 10 | 0.500 |
Why?
|
| Male | 29 | 2024 | 41953 | 0.500 |
Why?
|
| Cryptococcus neoformans | 3 | 2020 | 9 | 0.480 |
Why?
|
| Respiratory Mucosa | 1 | 2014 | 88 | 0.470 |
Why?
|
| Mice, Transgenic | 10 | 2021 | 1570 | 0.470 |
Why?
|
| Cells, Cultured | 12 | 2022 | 2874 | 0.470 |
Why?
|
| Tularemia | 2 | 2013 | 8 | 0.470 |
Why?
|
| Communicable Disease Control | 1 | 2014 | 50 | 0.460 |
Why?
|
| Leukocyte L1 Antigen Complex | 2 | 2024 | 45 | 0.460 |
Why?
|
| Bacterial Vaccines | 1 | 2013 | 42 | 0.450 |
Why?
|
| Mexico | 4 | 2021 | 68 | 0.450 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2013 | 105 | 0.450 |
Why?
|
| Communicable Diseases | 1 | 2014 | 63 | 0.450 |
Why?
|
| Bone Marrow | 3 | 2024 | 444 | 0.440 |
Why?
|
| Immunity | 4 | 2022 | 139 | 0.440 |
Why?
|
| Lipocalins | 1 | 2012 | 34 | 0.430 |
Why?
|
| Acute-Phase Proteins | 1 | 2012 | 37 | 0.430 |
Why?
|
| Toll-Like Receptors | 1 | 2013 | 92 | 0.420 |
Why?
|
| Oncogene Proteins | 1 | 2012 | 61 | 0.420 |
Why?
|
| Periodontitis | 1 | 2012 | 7 | 0.420 |
Why?
|
| Alveolar Bone Loss | 1 | 2012 | 20 | 0.420 |
Why?
|
| Drug Discovery | 1 | 2013 | 107 | 0.420 |
Why?
|
| Cardiovascular Diseases | 1 | 2019 | 705 | 0.420 |
Why?
|
| Th2 Cells | 5 | 2021 | 147 | 0.420 |
Why?
|
| T-Lymphocytes | 6 | 2022 | 1220 | 0.400 |
Why?
|
| Periodicals as Topic | 1 | 2014 | 168 | 0.400 |
Why?
|
| Interleukin-12 Receptor beta 1 Subunit | 1 | 2011 | 2 | 0.400 |
Why?
|
| Anti-Retroviral Agents | 2 | 2022 | 31 | 0.390 |
Why?
|
| Myeloid-Derived Suppressor Cells | 2 | 2021 | 25 | 0.380 |
Why?
|
| Receptors, Interleukin-12 | 2 | 2010 | 9 | 0.380 |
Why?
|
| Interferons | 2 | 2022 | 134 | 0.380 |
Why?
|
| Neovascularization, Pathologic | 1 | 2013 | 364 | 0.370 |
Why?
|
| Gene Expression Profiling | 5 | 2022 | 1427 | 0.370 |
Why?
|
| Health Status Indicators | 1 | 2011 | 104 | 0.370 |
Why?
|
| Cryptococcosis | 3 | 2020 | 11 | 0.360 |
Why?
|
| Immunity, Active | 1 | 2010 | 9 | 0.360 |
Why?
|
| Health Surveys | 1 | 2011 | 239 | 0.360 |
Why?
|
| Chemokine CCL21 | 1 | 2009 | 16 | 0.360 |
Why?
|
| Antigens, Bacterial | 3 | 2017 | 135 | 0.350 |
Why?
|
| Lymphocyte Cooperation | 1 | 2009 | 5 | 0.350 |
Why?
|
| Psychometrics | 1 | 2011 | 328 | 0.340 |
Why?
|
| Gene Expression | 3 | 2021 | 1311 | 0.340 |
Why?
|
| Homeostasis | 2 | 2019 | 408 | 0.340 |
Why?
|
| Carrier Proteins | 1 | 2012 | 679 | 0.320 |
Why?
|
| Mutation | 4 | 2024 | 4097 | 0.310 |
Why?
|
| Adult | 12 | 2024 | 26303 | 0.310 |
Why?
|
| HIV Infections | 5 | 2021 | 827 | 0.310 |
Why?
|
| Influenza A virus | 2 | 2022 | 169 | 0.310 |
Why?
|
| Transcriptome | 3 | 2021 | 623 | 0.280 |
Why?
|
| Toll-Like Receptor 2 | 4 | 2017 | 35 | 0.280 |
Why?
|
| Aged | 10 | 2021 | 18904 | 0.270 |
Why?
|
| Virulence | 4 | 2022 | 277 | 0.270 |
Why?
|
| Macrophages, Alveolar | 2 | 2019 | 57 | 0.270 |
Why?
|
| Disease Progression | 2 | 2021 | 1489 | 0.270 |
Why?
|
| Young Adult | 6 | 2021 | 6193 | 0.260 |
Why?
|
| Middle Aged | 12 | 2021 | 25649 | 0.260 |
Why?
|
| Pandemics | 2 | 2021 | 760 | 0.250 |
Why?
|
| CD11 Antigens | 1 | 2024 | 15 | 0.250 |
Why?
|
| Inflammation Mediators | 3 | 2017 | 155 | 0.250 |
Why?
|
| Pneumocystis | 2 | 2017 | 4 | 0.240 |
Why?
|
| I-kappa B Kinase | 1 | 2024 | 41 | 0.240 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 3 | 2022 | 56 | 0.240 |
Why?
|
| Luminescent Measurements | 1 | 2024 | 62 | 0.240 |
Why?
|
| Prospective Studies | 3 | 2021 | 4268 | 0.240 |
Why?
|
| Antigens, CD | 2 | 2016 | 465 | 0.230 |
Why?
|
| Bone Marrow Cells | 2 | 2023 | 259 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2021 | 1688 | 0.230 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2024 | 75 | 0.230 |
Why?
|
| ADP-Ribosylation | 1 | 2023 | 1 | 0.230 |
Why?
|
| Biosensing Techniques | 1 | 2024 | 73 | 0.220 |
Why?
|
| Nucleotidyltransferases | 1 | 2023 | 31 | 0.220 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2023 | 50 | 0.220 |
Why?
|
| Transforming Growth Factor beta | 2 | 2022 | 321 | 0.220 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 147 | 0.220 |
Why?
|
| Poliomyelitis | 1 | 2022 | 28 | 0.220 |
Why?
|
| Transforming Growth Factors | 1 | 2022 | 12 | 0.210 |
Why?
|
| Hematopoiesis | 1 | 2023 | 164 | 0.210 |
Why?
|
| Genetic Predisposition to Disease | 5 | 2018 | 2322 | 0.210 |
Why?
|
| Cluster Analysis | 1 | 2023 | 371 | 0.210 |
Why?
|
| Survival Analysis | 3 | 2021 | 1542 | 0.210 |
Why?
|
| Integrins | 1 | 2022 | 78 | 0.210 |
Why?
|
| HIV-1 | 2 | 2020 | 164 | 0.210 |
Why?
|
| Transcription Factors | 2 | 2023 | 1645 | 0.200 |
Why?
|
| Cell Proliferation | 4 | 2019 | 1642 | 0.200 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2021 | 7 | 0.200 |
Why?
|
| Enterococcus faecalis | 1 | 2022 | 54 | 0.200 |
Why?
|
| Cell Degranulation | 1 | 2021 | 14 | 0.190 |
Why?
|
| Giant Cells | 1 | 2021 | 19 | 0.190 |
Why?
|
| Mice, 129 Strain | 2 | 2021 | 57 | 0.190 |
Why?
|
| Sickness Impact Profile | 1 | 2001 | 27 | 0.190 |
Why?
|
| Monkey Diseases | 1 | 2020 | 9 | 0.190 |
Why?
|
| DNA Repair | 1 | 2023 | 359 | 0.190 |
Why?
|
| Callithrix | 1 | 2020 | 12 | 0.190 |
Why?
|
| Flow Cytometry | 3 | 2014 | 691 | 0.190 |
Why?
|
| Mitochondria | 2 | 2022 | 548 | 0.190 |
Why?
|
| Xylose | 1 | 2020 | 23 | 0.190 |
Why?
|
| Papio | 1 | 2020 | 82 | 0.190 |
Why?
|
| Immunophenotyping | 1 | 2021 | 217 | 0.190 |
Why?
|
| Lung Diseases, Fungal | 1 | 2020 | 18 | 0.180 |
Why?
|
| Patient Outcome Assessment | 1 | 2021 | 84 | 0.180 |
Why?
|
| CD11b Antigen | 1 | 2020 | 36 | 0.180 |
Why?
|
| Monosaccharide Transport Proteins | 1 | 2020 | 73 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 34 | 0.180 |
Why?
|
| Stroke Rehabilitation | 1 | 2001 | 41 | 0.180 |
Why?
|
| Epigenesis, Genetic | 1 | 2024 | 502 | 0.180 |
Why?
|
| Interleukin-1beta | 2 | 2024 | 81 | 0.180 |
Why?
|
| Nitric Oxide Synthase Type II | 2 | 2013 | 87 | 0.180 |
Why?
|
| Species Specificity | 2 | 2020 | 685 | 0.180 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2020 | 80 | 0.180 |
Why?
|
| Macaca | 1 | 2020 | 88 | 0.170 |
Why?
|
| Monocytes | 1 | 2021 | 217 | 0.170 |
Why?
|
| Pulmonary Medicine | 1 | 2020 | 46 | 0.170 |
Why?
|
| Activities of Daily Living | 1 | 2001 | 207 | 0.170 |
Why?
|
| Time Factors | 4 | 2019 | 5309 | 0.170 |
Why?
|
| Chronic Disease | 3 | 2017 | 948 | 0.170 |
Why?
|
| Mucosal-Associated Invariant T Cells | 1 | 2019 | 11 | 0.170 |
Why?
|
| Prognosis | 3 | 2021 | 3749 | 0.160 |
Why?
|
| Adoptive Transfer | 2 | 2016 | 169 | 0.160 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2018 | 11 | 0.160 |
Why?
|
| Interleukin-1 | 1 | 2018 | 71 | 0.160 |
Why?
|
| Chemokine CCL2 | 1 | 2018 | 47 | 0.160 |
Why?
|
| Stem Cells | 1 | 2021 | 369 | 0.160 |
Why?
|
| Adolescent | 4 | 2021 | 9141 | 0.160 |
Why?
|
| Immune Tolerance | 1 | 2021 | 338 | 0.160 |
Why?
|
| Tuberculoma | 1 | 2017 | 2 | 0.160 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 4 | 1 | 2017 | 1 | 0.160 |
Why?
|
| Antigen Presentation | 2 | 2016 | 215 | 0.160 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1976 | 0.150 |
Why?
|
| Models, Immunological | 2 | 2009 | 81 | 0.150 |
Why?
|
| RNA, Messenger | 5 | 2017 | 2008 | 0.150 |
Why?
|
| Mycobacterium leprae | 1 | 2017 | 6 | 0.150 |
Why?
|
| Interferon-beta | 1 | 2018 | 126 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2018 | 2399 | 0.150 |
Why?
|
| RNA | 1 | 2022 | 575 | 0.150 |
Why?
|
| Phagocytosis | 1 | 2017 | 86 | 0.150 |
Why?
|
| Child | 3 | 2024 | 7081 | 0.150 |
Why?
|
| Tryptophan | 1 | 2017 | 91 | 0.150 |
Why?
|
| Pneumocystis Infections | 1 | 2017 | 3 | 0.150 |
Why?
|
| Virus Activation | 1 | 2017 | 41 | 0.150 |
Why?
|
| Jordan | 2 | 2011 | 10 | 0.150 |
Why?
|
| Infant | 1 | 2024 | 3113 | 0.140 |
Why?
|
| Leprosy | 1 | 2016 | 8 | 0.140 |
Why?
|
| Integrin alpha Chains | 1 | 2016 | 16 | 0.140 |
Why?
|
| Lipids | 1 | 2018 | 271 | 0.140 |
Why?
|
| Cystic Fibrosis | 1 | 2018 | 117 | 0.140 |
Why?
|
| Administration, Intranasal | 1 | 2017 | 136 | 0.140 |
Why?
|
| Indians, North American | 1 | 2016 | 47 | 0.140 |
Why?
|
| Child, Preschool | 1 | 2024 | 3671 | 0.140 |
Why?
|
| Succinate Dehydrogenase | 1 | 2016 | 17 | 0.140 |
Why?
|
| Succinates | 1 | 2016 | 21 | 0.140 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2017 | 155 | 0.140 |
Why?
|
| Immunohistochemistry | 2 | 2013 | 1790 | 0.140 |
Why?
|
| Schistosoma mansoni | 1 | 2015 | 17 | 0.130 |
Why?
|
| Schistosomiasis mansoni | 1 | 2015 | 9 | 0.130 |
Why?
|
| Arginase | 1 | 2015 | 16 | 0.130 |
Why?
|
| Gene Expression Regulation, Fungal | 1 | 2016 | 61 | 0.130 |
Why?
|
| Bronchoalveolar Lavage | 3 | 2022 | 26 | 0.130 |
Why?
|
| Sigma Factor | 1 | 2015 | 23 | 0.130 |
Why?
|
| Cell Differentiation | 4 | 2024 | 1513 | 0.130 |
Why?
|
| Regulon | 1 | 2015 | 16 | 0.130 |
Why?
|
| HLA Antigens | 1 | 2016 | 226 | 0.130 |
Why?
|
| Fungal Proteins | 1 | 2016 | 141 | 0.130 |
Why?
|
| Vaccines, DNA | 1 | 2015 | 18 | 0.130 |
Why?
|
| Lymph Nodes | 2 | 2011 | 547 | 0.130 |
Why?
|
| Th1-Th2 Balance | 1 | 2014 | 4 | 0.130 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 6713 | 0.130 |
Why?
|
| Receptors, Interleukin-17 | 2 | 2017 | 10 | 0.120 |
Why?
|
| Hypoxia | 2 | 2022 | 650 | 0.120 |
Why?
|
| Biomedical Research | 1 | 2019 | 389 | 0.120 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2014 | 5 | 0.120 |
Why?
|
| Chemotaxis | 1 | 2014 | 73 | 0.120 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2014 | 13 | 0.120 |
Why?
|
| Intracellular Space | 1 | 2014 | 38 | 0.120 |
Why?
|
| Cytoprotection | 1 | 2014 | 47 | 0.120 |
Why?
|
| Cohort Studies | 1 | 2021 | 2833 | 0.120 |
Why?
|
| Protein Kinases | 1 | 2015 | 212 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 20 | 0.120 |
Why?
|
| Aerosols | 3 | 2015 | 44 | 0.110 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2021 | 379 | 0.110 |
Why?
|
| Cyclic GMP | 1 | 2013 | 59 | 0.110 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 312 | 0.110 |
Why?
|
| Enterotoxins | 1 | 2013 | 20 | 0.110 |
Why?
|
| Oropharynx | 1 | 2012 | 15 | 0.110 |
Why?
|
| Chemokine CXCL9 | 1 | 2012 | 7 | 0.110 |
Why?
|
| Lipocalin-2 | 1 | 2012 | 36 | 0.110 |
Why?
|
| Candida albicans | 1 | 2012 | 32 | 0.110 |
Why?
|
| Siderophores | 1 | 2012 | 22 | 0.110 |
Why?
|
| Candidiasis | 1 | 2012 | 37 | 0.110 |
Why?
|
| Mouth Mucosa | 1 | 2012 | 67 | 0.110 |
Why?
|
| Disease Susceptibility | 1 | 2013 | 199 | 0.110 |
Why?
|
| Influenza Vaccines | 1 | 2013 | 145 | 0.110 |
Why?
|
| Genetic Vectors | 1 | 2014 | 443 | 0.100 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2013 | 91 | 0.100 |
Why?
|
| Iron | 1 | 2012 | 166 | 0.100 |
Why?
|
| Asthma | 1 | 2020 | 973 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2013 | 279 | 0.100 |
Why?
|
| Receptors, CCR7 | 1 | 2011 | 16 | 0.100 |
Why?
|
| Calcium-Binding Proteins | 1 | 2012 | 121 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2012 | 166 | 0.100 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 927 | 0.100 |
Why?
|
| DNA-Binding Proteins | 2 | 2015 | 1239 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2012 | 182 | 0.100 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2010 | 18 | 0.100 |
Why?
|
| Chlamydia muridarum | 1 | 2010 | 2 | 0.090 |
Why?
|
| Pneumonia, Bacterial | 1 | 2010 | 29 | 0.090 |
Why?
|
| Acute Disease | 1 | 2012 | 838 | 0.090 |
Why?
|
| Salmonella typhimurium | 1 | 2010 | 32 | 0.090 |
Why?
|
| Molecular Targeted Therapy | 1 | 2013 | 283 | 0.090 |
Why?
|
| Immunoglobulin M | 1 | 2010 | 163 | 0.090 |
Why?
|
| Natural Killer T-Cells | 1 | 2010 | 44 | 0.090 |
Why?
|
| Viral Load | 2 | 2020 | 154 | 0.090 |
Why?
|
| Lymphocyte Depletion | 2 | 2020 | 98 | 0.090 |
Why?
|
| Vaccines, Attenuated | 2 | 2021 | 51 | 0.090 |
Why?
|
| B7-H1 Antigen | 2 | 2022 | 269 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2009 | 47 | 0.080 |
Why?
|
| Risk Factors | 1 | 2020 | 5439 | 0.080 |
Why?
|
| Interleukin-23 Subunit p19 | 2 | 2006 | 7 | 0.080 |
Why?
|
| Case-Control Studies | 3 | 2021 | 1848 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 2021 | 154 | 0.080 |
Why?
|
| Yersinia pestis | 1 | 2008 | 24 | 0.080 |
Why?
|
| Plague | 1 | 2008 | 27 | 0.080 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 1142 | 0.080 |
Why?
|
| Staphylococcal Infections | 1 | 2010 | 268 | 0.080 |
Why?
|
| Cell Lineage | 1 | 2009 | 291 | 0.080 |
Why?
|
| Bacterial Load | 2 | 2020 | 18 | 0.070 |
Why?
|
| HIV | 2 | 2017 | 48 | 0.070 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2008 | 213 | 0.070 |
Why?
|
| Sensitivity and Specificity | 2 | 2021 | 2019 | 0.070 |
Why?
|
| Interleukin-12 Subunit p35 | 1 | 2005 | 1 | 0.070 |
Why?
|
| Dose-Response Relationship, Immunologic | 1 | 2005 | 42 | 0.070 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2009 | 699 | 0.070 |
Why?
|
| Receptors, Cytokine | 1 | 2004 | 28 | 0.060 |
Why?
|
| Nitric Oxide Synthase | 1 | 2005 | 126 | 0.060 |
Why?
|
| GTP-Binding Proteins | 1 | 2005 | 147 | 0.060 |
Why?
|
| Reproducibility of Results | 1 | 2011 | 2744 | 0.060 |
Why?
|
| Luminescence | 1 | 2024 | 21 | 0.060 |
Why?
|
| Luciferases | 1 | 2024 | 128 | 0.060 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2024 | 98 | 0.060 |
Why?
|
| Immunotherapy | 1 | 2009 | 660 | 0.060 |
Why?
|
| Down-Regulation | 1 | 2005 | 519 | 0.060 |
Why?
|
| Genetic Association Studies | 2 | 2016 | 294 | 0.060 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2024 | 205 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1764 | 0.060 |
Why?
|
| Poliovirus Vaccine, Oral | 1 | 2022 | 4 | 0.050 |
Why?
|
| Child Mortality | 1 | 2022 | 6 | 0.050 |
Why?
|
| Immunization Programs | 1 | 2022 | 24 | 0.050 |
Why?
|
| Phenotype | 2 | 2019 | 2434 | 0.050 |
Why?
|
| Thorax | 1 | 2022 | 77 | 0.050 |
Why?
|
| Mice, Inbred BALB C | 2 | 2017 | 1086 | 0.050 |
Why?
|
| Immunity, Heterologous | 1 | 2021 | 1 | 0.050 |
Why?
|
| Inhalation Exposure | 1 | 2021 | 30 | 0.050 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2021 | 85 | 0.050 |
Why?
|
| Chromatin | 1 | 2024 | 396 | 0.050 |
Why?
|
| Mycobacterium | 1 | 2021 | 18 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2021 | 13 | 0.050 |
Why?
|
| Particulate Matter | 1 | 2022 | 102 | 0.050 |
Why?
|
| Rehabilitation Centers | 1 | 2001 | 8 | 0.050 |
Why?
|
| Occupational Therapy | 1 | 2001 | 16 | 0.050 |
Why?
|
| Symptom Assessment | 1 | 2021 | 65 | 0.050 |
Why?
|
| Virus Shedding | 1 | 2020 | 27 | 0.050 |
Why?
|
| Healthy Volunteers | 1 | 2021 | 145 | 0.050 |
Why?
|
| Trehalose | 1 | 2020 | 4 | 0.050 |
Why?
|
| Bronchoalveolar Lavage Fluid | 1 | 2020 | 124 | 0.050 |
Why?
|
| Linear Models | 1 | 2021 | 423 | 0.050 |
Why?
|
| Immunoglobulin mu-Chains | 1 | 2020 | 18 | 0.050 |
Why?
|
| Host-Parasite Interactions | 1 | 2020 | 30 | 0.050 |
Why?
|
| Receptors, Notch | 1 | 2021 | 123 | 0.050 |
Why?
|
| Physical Therapy Modalities | 1 | 2001 | 83 | 0.050 |
Why?
|
| Disability Evaluation | 1 | 2001 | 138 | 0.040 |
Why?
|
| Mammals | 1 | 2022 | 235 | 0.040 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2020 | 73 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2020 | 100 | 0.040 |
Why?
|
| Probability | 1 | 2001 | 356 | 0.040 |
Why?
|
| Lentivirus | 1 | 2019 | 37 | 0.040 |
Why?
|
| Biological Transport | 1 | 2020 | 399 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2021 | 1020 | 0.040 |
Why?
|
| Cytological Techniques | 1 | 2019 | 30 | 0.040 |
Why?
|
| Simian virus 40 | 1 | 2019 | 35 | 0.040 |
Why?
|
| Collagen | 1 | 2021 | 295 | 0.040 |
Why?
|
| Recovery of Function | 1 | 2001 | 290 | 0.040 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 306 | 0.040 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2021 | 421 | 0.040 |
Why?
|
| Immunoglobulin G | 1 | 2020 | 466 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2021 | 1048 | 0.040 |
Why?
|
| Antiviral Agents | 1 | 2022 | 514 | 0.040 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2024 | 565 | 0.040 |
Why?
|
| Proteomics | 1 | 2019 | 227 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2017 | 307 | 0.040 |
Why?
|
| Administration, Inhalation | 1 | 2017 | 188 | 0.040 |
Why?
|
| GATA3 Transcription Factor | 1 | 2017 | 48 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2017 | 38 | 0.040 |
Why?
|
| STAT3 Transcription Factor | 1 | 2017 | 85 | 0.040 |
Why?
|
| Cell Hypoxia | 1 | 2017 | 170 | 0.040 |
Why?
|
| Dimerization | 2 | 2008 | 143 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2019 | 635 | 0.040 |
Why?
|
| Succinic Acid | 1 | 2016 | 7 | 0.040 |
Why?
|
| Cell Respiration | 1 | 2016 | 18 | 0.040 |
Why?
|
| RNA Interference | 1 | 2017 | 377 | 0.030 |
Why?
|
| Homeodomain Proteins | 1 | 2020 | 553 | 0.030 |
Why?
|
| Drug Resistance | 1 | 2017 | 232 | 0.030 |
Why?
|
| Melanins | 1 | 2016 | 23 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2016 | 478 | 0.030 |
Why?
|
| Cell Line | 1 | 2020 | 2498 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 1842 | 0.030 |
Why?
|
| Reperfusion Injury | 1 | 2016 | 139 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2016 | 292 | 0.030 |
Why?
|
| Gene Frequency | 1 | 2016 | 684 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2021 | 2285 | 0.030 |
Why?
|
| Chemotactic Factors | 1 | 2013 | 14 | 0.030 |
Why?
|
| Toll-Like Receptor 6 | 1 | 2013 | 5 | 0.030 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 1 | 2013 | 15 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2017 | 536 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2016 | 487 | 0.030 |
Why?
|
| Gene Regulatory Networks | 1 | 2016 | 307 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 1131 | 0.030 |
Why?
|
| Demography | 1 | 2013 | 181 | 0.030 |
Why?
|
| Polymorphism, Genetic | 1 | 2016 | 824 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 541 | 0.030 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2013 | 126 | 0.030 |
Why?
|
| Linkage Disequilibrium | 1 | 2013 | 474 | 0.030 |
Why?
|
| Dinoprostone | 1 | 2011 | 70 | 0.030 |
Why?
|
| Paracrine Communication | 1 | 2011 | 32 | 0.030 |
Why?
|
| Immunomodulation | 1 | 2011 | 56 | 0.020 |
Why?
|
| Stroke | 1 | 2001 | 978 | 0.020 |
Why?
|
| Haplotypes | 1 | 2013 | 637 | 0.020 |
Why?
|
| Pneumocystis carinii | 1 | 2010 | 3 | 0.020 |
Why?
|
| beta-Glucans | 1 | 2010 | 5 | 0.020 |
Why?
|
| Immune Sera | 1 | 2010 | 52 | 0.020 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2010 | 131 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 2010 | 99 | 0.020 |
Why?
|
| Mice, SCID | 1 | 2010 | 261 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1204 | 0.020 |
Why?
|
| Pneumonia | 1 | 2011 | 183 | 0.020 |
Why?
|
| Lipid A | 1 | 2008 | 3 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2021 | 8151 | 0.020 |
Why?
|
| Insect Vectors | 1 | 2008 | 10 | 0.020 |
Why?
|
| Siphonaptera | 1 | 2008 | 8 | 0.020 |
Why?
|
| Acyltransferases | 1 | 2008 | 41 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2010 | 210 | 0.020 |
Why?
|
| Acetylation | 1 | 2008 | 132 | 0.020 |
Why?
|
| Hot Temperature | 1 | 2008 | 207 | 0.020 |
Why?
|
| Staphylococcus aureus | 1 | 2010 | 274 | 0.020 |
Why?
|
| Kinetics | 1 | 2010 | 1528 | 0.020 |
Why?
|
| Escherichia coli Proteins | 1 | 2008 | 182 | 0.020 |
Why?
|
| Retrospective Studies | 1 | 2001 | 8869 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1484 | 0.020 |
Why?
|
| Growth Inhibitors | 1 | 2006 | 42 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 3029 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2008 | 604 | 0.020 |
Why?
|
| Phylogeny | 1 | 2010 | 1170 | 0.020 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2004 | 39 | 0.020 |
Why?
|
| Receptors, Interleukin | 1 | 2004 | 36 | 0.020 |
Why?
|
| Lymphocyte Count | 1 | 2004 | 98 | 0.020 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2004 | 88 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 235 | 0.010 |
Why?
|